



an Open Access Journal by MDPI

Advanced Molecular Research on Ovarian Cancer

Guest Editors:

Dr. Fulvio Borella

Dipartimento di Scienze
Chirurgiche, Università degli
Studi di Torino (UNITO), Turin,
Italy

Dr. Luca Bertero

Pathology Unit, Department of
Medical Sciences, University of
Turin and “Città della Salute e
della Scienza” University
Hospital, Via Santena 7, 10126
Torino, Italy

Dr. Stefano Cosma

Scuola di Medicina, Università
degli Studi di Torino, Turin, Italy

Deadline for manuscript
submissions:

closed (31 May 2023)

Message from the Guest Editors

Dear Colleagues,

Recent advances in cancer molecular biology have allowed for the development of new therapeutic options.

Unlike traditional drugs that inhibit DNA synthesis and interfere with the tumor cells' cycle, these target drugs act on molecular signaling pathways of cancer cells, stroma, vascularization, and the immune microenvironment.

Most first-line treatments are still based on platinum and taxol; however, new target therapies have emerged over the last decade: drugs targeting defective DNA repair mechanisms, such as PARP inhibitors, or targeting angiogenesis, in particular anti-VEGF antibodies, have been used in the treatment of advanced ovarian cancers. In addition, immunotherapy-based treatment has received much attention in recent years.

This Special Issue will highlight recent advances and future directions in molecular mechanisms and target therapies regarding ovarian cancer. We welcome preclinical studies that may lead to a better understanding of this rapidly evolving field.

Dr. Fulvio Borella
Dr. Luca Bertero
Dr. Stefano Cosma
Guest Editors



mdpi.com/si/127669

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI